Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Short Interest Update

by · The Cerbat Gem

Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Get Free Report) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 45,400 shares, an increase of 168.6% from the October 15th total of 16,900 shares. Based on an average daily volume of 90,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 1.7% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Oncternal Therapeutics in a research note on Monday. They issued a “hold” rating on the stock. Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Northland Securities reiterated a “market perform” rating and set a $2.00 price objective on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Finally, HC Wainwright dropped their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $20.00.

Get Our Latest Report on ONCT

Oncternal Therapeutics Price Performance

Shares of Oncternal Therapeutics stock traded up $0.03 on Friday, hitting $1.14. The company had a trading volume of 61,780 shares, compared to its average volume of 34,770. The business has a 50-day simple moving average of $1.63 and a 200-day simple moving average of $5.21. The company has a market cap of $3.37 million, a PE ratio of -0.09 and a beta of 1.33. Oncternal Therapeutics has a 52 week low of $1.03 and a 52 week high of $13.14.

Hedge Funds Weigh In On Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the second quarter, according to its most recent filing with the SEC. The firm bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics at the end of the most recent quarter. 16.05% of the stock is owned by institutional investors.

Oncternal Therapeutics Company Profile

(Get Free Report)

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.

See Also